IFNG and neoplasm: Increases plasmacytoid DC and B cells through TLR-9 and TLR-4 potentiating the Th1 pathway with higher IFN-γ and IL-12 secretion by dendritic cells. In antitumor vaccines increases the average antibody titers against tumor-specific antigen, and the anti–tumor antigen CD4+ T cells.